| Literature DB >> 27942045 |
David Allaway1, Matthew S Gilham1, Alison Colyer1, Thomas J Jönsson2, Kelly S Swanson3, Penelope J Morris1.
Abstract
Neutering is a significant risk factor for obesity in cats. The mechanisms that promote neuter-associated weight gain are not well understood but following neutering, acute changes in energy expenditure and energy consumption have been observed. Metabolic profiling (GC-MS and UHPLC-MS-MS) was used in a longitudinal study to identify changes associated with age, sexual development and neutering in male cats fed a nutritionally-complete dry diet to maintain an ideal body condition score. At eight time points, between 19 and 52 weeks of age, fasted blood samples were taken from kittens neutered at either 19 weeks of age (Early Neuter (EN), n = 8) or at 31 weeks of age (Conventional Neuter (CN), n = 7). Univariate and multivariate analyses were used to compare plasma metabolites (n = 370) from EN and CN cats. Age was the primary driver of variance in the plasma metabolome, including a developmental change independent of neuter group between 19 and 21 weeks in lysolipids and fatty acid amides. Changes associated with sexual development and its subsequent loss were also observed, with differences at some time points observed between EN and CN cats for 45 metabolites (FDR p<0.05). Pathway Enrichment Analysis also identified significant effects in 20 pathways, dominated by amino acid, sterol and fatty acid metabolism. Most changes were interpretable within the context of male sexual development, and changed following neutering in the CN group. Felinine metabolism in CN cats was the most significantly altered pathway, increasing during sexual development and decreasing acutely following neutering. Felinine is a testosterone-regulated, felid-specific glutathione derivative secreted in urine. Alterations in tryptophan, histidine and tocopherol metabolism observed in peripubertal cats may be to support physiological functions of glutathione following diversion of S-amino acids for urinary felinine secretion.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27942045 PMCID: PMC5152928 DOI: 10.1371/journal.pone.0168144
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Principal Component Analysis of metabolic profiles from males indicating the impact of age on variance in the plasma metabolome.
PCA of plasma metabolome samples from males, labelled by neuter group and age, indicate that age is the primary driver of variance between samples. The PCA scores plot of metabolites (with 95% confidence ellipses by neuter group at 19, 31 and 43 weeks) illustrates the divergence between groups at week 31.
Metabolite data used to support a discrete developmental change that ended between 19 and 21 weeks old.
| Early Neuter:Age21-Age19 | Conventional Neuter:Age21-Age19 | ||||||
|---|---|---|---|---|---|---|---|
| Metabolite | Fold change | Confidence interval (95%) | FDR | Fold change | Confidence interval (95%) | FDR | |
| 0.31 | (0.2,0.47) | <0.0001 | 0.2 | (0.12,0.31) | <0.0001 | ||
| 0.17 | (0.1,0.27) | <0.0001 | 0.14 | (0.08,0.24) | <0.0001 | ||
| 0.04 | (0.02,0.1) | <0.0001 | 0.06 | (0.02,0.16) | <0.0001 | ||
| 0.25 | (0.17,0.37) | <0.0001 | 0.33 | (0.21,0.51) | <0.0001 | ||
| 0.36 | (0.27,0.48) | <0.0001 | 0.41 | (0.3,0.55) | <0.0001 | ||
| 0.56 | (0.43,0.73) | 0.0006 | 0.35 | (0.26,0.46) | <0.0001 | ||
| 0.21 | (0.11,0.38) | <0.0001 | 0.11 | (0.06,0.2) | <0.0001 | ||
| 0.26 | (0.18,0.37) | <0.0001 | 0.27 | (0.18,0.39) | <0.0001 | ||
| 0.3 | (0.19,0.47) | <0.0001 | 0.13 | (0.08,0.21) | <0.0001 | ||
| 0.39 | (0.29,0.52) | <0.0001 | 0.4 | (0.3,0.55) | <0.0001 | ||
| 0.35 | (0.24,0.5) | <0.0001 | 0.36 | (0.25,0.53) | <0.0001 | ||
| 0.74 | (0.62,0.88) | 0.0106 | 0.64 | (0.53,0.77) | <0.0001 | ||
| 0.29 | (0.17,0.48) | <0.0001 | 0.19 | (0.11,0.34) | <0.0001 | ||
| 0.4 | (0.3,0.54) | <0.0001 | 0.37 | (0.27,0.5) | <0.0001 | ||
| 0.19 | (0.11,0.33) | <0.0001 | 0.21 | (0.11,0.37) | <0.0001 | ||
| 0.76 | (0.65,0.89) | 0.0119 | 0.61 | (0.52,0.72) | <0.0001 | ||
Metabolites that altered significantly (FDR corrected p<0.05) between weeks 19 and 21 of age in both neuter groups with fold-change in means with 95% Confidence Intervals. All metabolites belonged to two groups of lipids, fatty acid amides and glycerophosphocholine lysolipids.
*Putative identification: no standard metabolite tested.
Fig 2Examples of metabolites which decline between 19 and 21 weeks of age.
Changes in the average abundance of metabolites for which significant changes were observed between 19 and 21 weeks of age in males in both neuter groups, CN (red) and EN (black), all of which were present in only 2 lipid metabolite subgroups (see Table 2 for details). Scaled intensity is relative to the normalised pool of all samples (error bars represent 95% CI).
Metabolites differing at some stage between neuter groups.
| Ranking | Subpathway | Metabolite | 19 Weeks | 21 Weeks | 25 weeks | 31 weeks | 33 weeks | 37 weeks | 43 weeks | 52 weeks |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 0.92 | 1.68 | 1.42 | 1.11 | ||||||
| 2 | 0.91 | 1.47 | 1.4 | 1.06 | ||||||
| 3 | 0.84 | 1.35 | 1.78 | 1.35 | 0.97 | |||||
| 4 | Tryptophan metabolism | kynurenine | 0.98 | 1.06 | 0.86 | 0.96 | 0.93 | |||
| 5 | Fatty acid, dihydroxy | 2-hydroxydecanoic acid | 0.91 | 0.89 | 1.02 | 1.16 | 1.47 | |||
| 6 | 0.93 | 1.3 | 1.77 | 1.91 | 1.22 | 0.98 | ||||
| 7 | 1.03 | 1.09 | 2.02 | 2.01 | 2.13 | |||||
| 8 | Tryptophan metabolism | tryptophan | 1.08 | 1.12 | 0.97 | 0.85 | 0.94 | 1.05 | 1.03 | |
| 9 | Fatty acid, dicarboxylate | eicosanodioate | 1.16 | 1.17 | 0.91 | 0.96 | 1.05 | 1 | ||
| 10 | Lysolipid | 1-docosahexaenoylglycerophosphocholine | 1.05 | 0.78 | 0.78 | 0.83 | 0.96 | 0.95 | 1.14 | |
| 11 | Cysteine, methionine, SAM, taurine metabolism | N-acetylmethionine | 1 | 0.92 | 0.7 | 0.76 | 0.91 | 0.86 | ||
| 12 | Pyrimidine metabolism, thymine containing | thymidine | 0.85 | 0.92 | 1.63 | 1.65 | 1.07 | 1.17 | 1.18 | |
| 13 | Tocopherol metabolism | alpha-tocopherol | 1.08 | 1.21 | 1.24 | 1.12 | 1.04 | 1.18 | 1.09 | |
| 14 | Sphingolipid | palmitoyl sphingomyelin | 1.08 | 1.31 | 0.95 | 0.95 | 1.06 | 1.02 | ||
| 15 | Histidine metabolism | histidine | 0.98 | 0.93 | 0.89 | 0.97 | 0.96 | 0.99 | 1.04 | |
| 16 | Lysolipid | 1-palmitoylglycerophosphoethanolamine | 0.95 | 0.89 | 0.66 | 1.13 | 1.03 | 0.76 | ||
| 17 | Sterol | cholesterol | 1.09 | 1.29 | 1.01 | 1.04 | 1.13 | 1.08 | ||
| 18 | 1.02 | 0.96 | 1.14 | 1.3 | 1.15 | 1.01 | 0.93 | |||
| 19 | Lysolipid | 1-docosapentaenoylglycerophosphocholine | 1.32 | 0.79 | 0.79 | 0.96 | 0.96 | 1.24 | 1.09 | |
| 20 | 0.95 | 0.89 | 0.86 | 1.06 | 1.01 | 0.96 | 0.89 | |||
| 21 | Valine, leucine and isoleucine metabolism | 2-methylbutyrylcarnitine (C5) | 0.97 | 1.11 | 0.86 | 0.81 | 0.98 | 1.08 | 1.11 | |
| 22 | Lysolipid | 1-oleoylglycerophosphoethanolamine | 0.87 | 1.23 | 1.11 | 0.8 | 1.28 | 1.5 | 0.81 | |
| 23 | Alanine and aspartate metabolism | N-acetylaspartate (NAA) | 2.02 | 1.22 | 1.71 | 1.85 | 1.13 | 1.03 | 1.63 | |
| 24 | Chemical | 2-ethylhexanoate | 1.03 | 1.53 | 1.57 | 0.91 | 1.26 | 1.14 | 1.1 | |
| 25 | Glycerolipid metabolism | glycerophosphorylcholine (GPC) | 1.02 | 1.14 | 1.1 | 0.93 | 0.92 | 1.05 | 0.89 | |
| 26 | Long chain fatty acid | cis-vaccenate (18:1n7) | 1.02 | 1.18 | 1.21 | 1.09 | 1.06 | 1.22 | 1.21 | |
| 27 | Urea cycle; arginine-, proline-, metabolism | citrulline | 1.04 | 1.07 | 0.77 | 0.78 | 0.92 | 0.88 | 1.05 | |
| 28 | Essential fatty acid | eicosapentaenoate (EPA; 20:5n3) | 1.04 | 0.92 | 0.88 | 0.8 | 1.04 | 1.01 | 1.32 | |
| 29 | Pyrimidine metabolism, cytidine containing | 5-methylcytidine | 1 | 1.02 | 0.9 | 0.82 | 0.98 | 0.79 | ||
| 30 | Benzoate metabolism | 2-aminobutyrate | 1.11 | 1.06 | 0.95 | 0.83 | 1.06 | 1.11 | 0.82 | |
| 31 | Benzoate metabolism | 4-vinylphenol sulfate | 0.62 | 0.83 | 1.13 | 0.85 | 0.67 | 0.9 | 1.02 | |
| 32 | Glutathione metabolism | 5-oxoproline | 1.02 | 1.04 | 1.01 | 0.88 | 0.93 | 1.02 | 1.02 | |
| 33 | Tryptophan metabolism | indolepropionate | 0.8 | 1.05 | 0.77 | 0.65 | 0.98 | 1.02 | ||
| 34 | Essential fatty acid | docosahexaenoate (DHA) 22.6n3. | 0.94 | 0.96 | 0.96 | 0.79 | 0.98 | 0.85 | 0.98 | |
| 35 | Fructose, mannose, galactose, starch, and sucrose metabolism | mannose | 1.04 | 1.18 | 1.24 | 1.01 | 1.13 | 1.14 | 1.07 | |
| 36 | Pyrimidine metabolism, cytidine containing | 2'-deoxycytidine | 1 | 0.99 | 1.02 | 0.84 | 0.83 | 0.99 | 0.94 | |
| 37 | Creatine metabolism | creatine | 1.27 | 1.25 | 1.23 | 1.58 | 1.54 | 1.55 | 1.3 | |
| 38 | 0.9 | 1.08 | 0.92 | 0.97 | 0.89 | 0.89 | 0.96 | |||
| 39 | Glutathione metabolism | glutathione, oxidized (GSSG) | 0.88 | 0.9 | 0.96 | 0.79 | 1.34 | 0.9 | 1.06 | |
| 40 | 1.08 | 0.96 | 1.06 | 0.87 | 0.82 | 0.77 | 1.1 | |||
| 41 | Urea cycle; arginine-, proline-, metabolism | trans-4-hydroxyproline | 0.91 | 1.13 | 1.02 | 1.07 | 0.82 | 0.88 | 0.78 | |
| 42 | Vitamin A metabolism | retinoate | 1.08 | 0.68 | 0.88 | 1.07 | 1.49 | 1.26 | 1.2 | |
| 43 | 1.05 | 1.19 | 1.07 | 0.95 | 0.87 | 1.08 | 1.13 | |||
| 44 | Purine metabolism, adenine containing | N1-methyladenosine | 1.07 | 1.07 | 0.88 | 0.89 | 0.92 | 0.89 | 0.92 | |
| 45 | 1.05 | 1.14 | 1.21 | 0.97 | 0.76 | 0.89 | 0.94 |
Fold-change values of the 45 named metabolites identified as significantly different (FDR corrected p<0.05) at some stage between the two neuter groups (highlighted in red, up in CN; highlighted in green, down in CN). A further 16 unknown metabolites also met this significance cut-off, with all differences between 25–37 weeks and 11 significantly different at week 31. The list is sorted by decreasing significance values at week 31, the time point with the largest number of significant differences.
Metabolites in bold belong to metabolic subpathways found to have more significant metabolite groups than would be expected by chance between the two neuter groups at some time point (see text).
a indicates subpathways that contained more significant metabolites than would be expected by chance within at least one of the neuter groups between timepoints.
*Putative identification: no standard metabolite tested.
Metabolic pathways that differ at some stage between or within neuter groups.
| Pathways that are over-represented with significant contrasts between | |||
|---|---|---|---|
| the two groups in at least one time point comparison | at least one time point within EN group | at least one time point within CN group | |
| Dipeptide | Y | Y | |
| Feline metabolism | Y | Y | |
| Tryptophan metabolism | Y | ||
| Endocannabinoid | Y | ||
| Fatty acid, dicarboxylate | Y | ||
| Lysolipid | Y | Y | |
| Dipeptide derivative | Y | Y | Y |
| Chemical | Y | Y | |
| Long chain fatty acid | Y | Y | |
| Urea cycle; arginine-, proline-, metabolism | Y | Y | |
| Essential fatty acid | Y | Y | |
| Benzoate metabolism | Y | ||
| Fatty acid, amide | Y | Y | |
| Glutathione metabolism | Y | ||
| Glycine, serine and threonine metabolism | Y | Y | |
| Fatty acid, monohydroxy | Y | ||
| Food component/Plant | Y | Y | |
| Purine metabolism, adenine containing | Y | ||
| Fatty acid metabolism | Y | ||
| Krebs cycle | Y | ||
Twenty pathways were found to contain more significant metabolite groups than would be expected by chance, for contrasts between groups and within groups, ranked to be consistent with the metabolites in Table 2.
aPathways for which no metabolite met the univariate significant criterion used between the two neuter groups.
Fig 3Impact of development and neutering on felinine-associated metabolites.
Changes in the average abundance of metabolites of the felinine pathway and a related dipeptide in the two groups (CN (red) and EN (black)). Scaled intensity is relative to the normalised pool of all samples (error bars represent 95% confidence intervals). *Putative identification: no standard metabolite tested. These four metabolites were highly correlated (r>0.95) in the CN group of males cats.
Fig 4Impact of development and neutering on tryptophan and sterol metabolism.
Changes in the average abundance of sterol- and tryptophan-associated metabolites with significant increases in CN compared to EN cats during sexual development ((CN (red) and EN (black)). Scaled intensity is relative to the normalised pool of all samples (error bars represent 95% CI).
Fig 5Impact of development and neutering on histidine-associated metabolites.
Changes in the average abundance of histidine and histidine-derived muscle-associated amino acid derivatives. Both histidine and carnosine decrease significantly in CN compared to EN cats during sexual development and increase to levels similar to EN cats within 2 weeks of neutering (CN (red) and EN (black)). Anserine, the final product detected in this pathway increases significantly in CN cats during sexual development and remains at a stable level, whilst EN cats show a steady increase throughout development. Scaled intensity is relative to the normalised pool of all samples (error bars represent 95% CI).
Fig 6Impact of development and neutering on S-amino acid-associated metabolism.
Changes in the average abundance of metabolites associated with the glutathione subpathway that differ significantly between neuter groups (CN (red) and EN (black)). Scaled intensity is relative to the normalised pool of all samples (error bars represent 95%CI).
Fig 7Impact of neutering on other metabolites associating with sexual development.
Changes in the average abundance of metabolites associated with sexual development in male cats identified as significantly different between EN and CN cats (CN (red) and EN (black)). Scaled intensity is relative to the normalised pool of all samples (error bars represent 95%CI).